CLINICAL_TRIALS ClinicalTrials.gov record update

Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04100694
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:47.120235+00:00
Published At: 2025-05-20T00:00:00+00:00
Record Updated At: 2025-05-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["NRG1 Fusion", "Pancreatic Cancer", "Non Small Cell Lung Cancer", "Solid Tumor, Unspecified, Adult", "Prostate Cancer", "Head and Neck Cancer", "Colorectal Cancer", "Breast Cancer", "Cholangiocarcinoma", "Renal Cell Carcinoma", "Unknown Primary Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-05-20"
protocolSection.identificationModule.nctId: "NCT04100694"
protocolSection.identificationModule.officialTitle: "Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor"
protocolSection.statusModule.overallStatus: "APPROVED_FOR_MARKETING"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.